Status:
UNKNOWN
Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment
Lead Sponsor:
Hospital de Niños R. Gutierrez de Buenos Aires
Conditions:
Chagas Disease
Eligibility:
All Genders
Up to 18 years
Brief Summary
Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial ...
Eligibility Criteria
Inclusion
- \- Patients between 0 and 18 years of age with confirmed Chagas disease (defined as patients under 8 months with positive parasitemia or older with 2 positive different techniques for serology) that received treatment with Nifurtimox or Benznidazole.
Exclusion
- \- Patients that abandoned follow-up
Key Trial Info
Start Date :
June 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT04274101
Start Date
June 1 2018
End Date
February 1 2025
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parasitology and Chagas Service, Buenos Aires Children´s Hospital Ricardo Gutierrez
Buenos Aires, Argentina, 1425